A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC

NCT02392507 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Necitumumab
DRUG: Nab-Paclitaxel
DRUG: Carboplatin

Sponsor

Eli Lilly and Company

Collaborators

[object Object]